公司資料

Aurinia Pharmaceuticals Inc 股價、新聞與催化劑

股票代碼:
AUPH
交易所:
NASDAQ
產業:
Biopharma
所在地:
Canada

股票表現

15.29 USD (-1.16%)

收盤價

最後更新: 2026年8月17日

1.98B USD

市值

股價為何變動

As of Aug 17, 2026, AUPH closed down 1.16% at $15.29. No new same-company headline was identified in the current news window.

公司概覽

業務概覽

Aurinia Pharmaceuticals is a biopharmaceutical company focused on autoimmune disease, especially kidney-related immune disorders. Its story combines commercial products with the challenge of maintaining growth in a specialty immunology market.

所在地與產業分類

Aurinia is headquartered in Canada and listed on NASDAQ. It sits in specialty biopharma with immunology and renal exposure.

商業模式特徵

The company depends on product sales, market access, and the ability to manage a focused franchise in autoimmune disease. Investors watch revenue, label strategy, and pipeline or portfolio updates.

生技產業定位

Aurinia occupies a durable specialty-immunology niche within biotech. It has commercial grounding, but the stock remains sensitive to execution and franchise durability.

未來催化劑

  • Aurinia’s catalysts are Lupkynis execution, lupus-nephritis adoption, and any label or commercial update that broadens the franchise. The market will care about whether growth stays steady.

近期新聞

    相似股票

    商業成熟度、治療領域或催化劑模式相近的同業公司。